ZyVersa Therapeutics (ZVSA)
OTHER OTC:ZVSA
Want to see ZVSA full AI Analyst Report?
Total Valuation
ZyVersa Therapeutics has a market cap or net worth of $1.42M. The enterprise value is $899.00M.
Market Cap$1.42M
Enterprise Value$899.00M
Share Statistics
ZyVersa Therapeutics has 8,095,921 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding8,095,921
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ZyVersa Therapeutics’s return on equity (ROE) is 2.01 and return on invested capital (ROIC) is 0.05%.
Return on Equity (ROE)2.01
Return on Assets (ROA)-71.72
Return on Invested Capital (ROIC)0.05%
Return on Capital Employed (ROCE)<0.01
Revenue Per Employee0.00
Profits Per Employee-3.56M
Employee Count7
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ZyVersa Therapeutics is ―. ZyVersa Therapeutics’s PEG ratio is 0.63.
PE Ratio―
PS Ratio0.00
PB Ratio-0.06
Price to Fair Value-0.06
Price to FCF-156.26
Price to Operating Cash Flow-0.62
PEG Ratio0.63
Income Statement
In the last 12 months, ZyVersa Therapeutics had revenue of 0.00 and earned -24.95M in profits. Earnings per share was -4.18.
Revenue0.00
Gross Profit0.00
Operating Income-6.84M
Pretax Income-25.80M
Net Income-24.95M
EBITDA-25.29M
Earnings Per Share (EPS)-4.18
Cash Flow
In the last 12 months, operating cash flow was -2.62B and capital expenditures 0.00, giving a free cash flow of -2.62B billion.
Operating Cash Flow-2.62B
Free Cash Flow-2.62B
Free Cash Flow per Share-323.77
Dividends & Yields
ZyVersa Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.37
52-Week Price Change-69.42%
50-Day Moving Average0.20
200-Day Moving Average0.18
Relative Strength Index (RSI)45.38
Average Volume (3m)51.59K
Important Dates
ZyVersa Therapeutics upcoming earnings date is Aug 24, 2026, Before Open (Confirmed).
Last Earnings DateMay 13, 2026
Next Earnings DateAug 24, 2026
Ex-Dividend Date―
Financial Position
ZyVersa Therapeutics as a current ratio of 0.03, with Debt / Equity ratio of -8.50%
Current Ratio0.03
Quick Ratio0.03
Debt to Market Cap0.00
Net Debt to EBITDA4.02
Interest Coverage Ratio-13.34
Taxes
In the past 12 months, ZyVersa Therapeutics has paid -851.66K in taxes.
Income Tax-851.66K
Effective Tax Rate0.03
Enterprise Valuation
ZyVersa Therapeutics EV to EBITDA ratio is -27.57, with an EV/FCF ratio of -0.14.
EV to Sales0.00
EV to EBITDA-27.57
EV to Free Cash Flow-0.14
EV to Operating Cash Flow-0.14
Balance Sheet
ZyVersa Therapeutics has $302.66M in cash and marketable securities with $1.20B in debt, giving a net cash position of -$897.34M billion.
Cash & Marketable Securities$302.66M
Total Debt$1.20B
Net Cash-$897.34M
Net Cash Per Share-$110.84
Tangible Book Value Per Share-$2.08
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for ZyVersa Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast57.26%